Baird’s CMC worked with Aeras, a public-private vaccine partnership, to look at the communications and policy drivers and barriers to adoption of a partially-effective new TB vaccine. The study focused on Brazil, Cambodia, China, India, Mozambique, Romania, Russia and South Africa. We conducted a perceptions study across the eight countries, conducting depth interviews with 86 key stakeholders and opinion leaders to identify the most likely scenario in each country for the adoption of a new TB vaccine.
Baird’s CMC presented respondents with different adoption scenarios, and asked “If this were the scenario, how likely would your country be to adopt it within three years of the first license anywhere?” Baird’s CMC then collated, analysed and synthesised the data: the respondents’ reactions to each scenario, the pros and cons of each scenario, views on costing, perceived health priorities, factors affecting the decisions, and key learnings.
From the findings, we presented recommendations and plans to encourage governments to plan now for adoption of new TB vaccines in the future. The recommendations covered communications, capacity building, stakeholder relations, government affairs and how to present data.